End-stage heart failure: The future of heart transplant and artificial heart

End-stage heart failure: The future of heart transplant and artificial heart

In the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:La Presse médicale (1983) 2024-03, Vol.53 (1), p.104191-104191, Article 104191
Hauptverfasser: Bounader, Karl, Flécher, Erwan
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology and cardiovascular system
Human health and pathology
Life Sciences
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 104191
container_issue 1
container_start_page 104191
container_title La Presse médicale (1983)
container_volume 53
creator Bounader, Karl
Flécher, Erwan
description In the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged heart failure, as bridge to transplant or as definitive implantation in non-transplant candidates. Although clinical results do not overcome those of HTx, improvement in the new generation of devices may help to reach the equipoise between the two therapies. This review will go through the evolution, current status and perspectives of both therapeutics.
doi_str_mv 10.1016/j.lpm.2023.104191
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04467355v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0755498223000283</els_id><sourcerecordid>2883583116</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-b0b256b0fdee042e62e196968380de9b634b7e24263fb37dde07e73acaa593123</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqXwA1hQRhhS_JHYMUxVVShSJJYyW058oa7yUeykEv8eVymMTOe7e-6V_CB0S_CcYMIfd_N638wppiz0CZHkDE0pJSzGVPBzNMUiTeNEZnSCrrzfYUxJIuQlmjCRyYwRPEX5qjWx7_UnRFvQro8qbevBwVO02UJUDX14R111WvZOt35f67aPdGuiMLKVLa2ux_01uqh07eHmVGfo42W1Wa7j_P31bbnI45Jloo8LXNCUF7gyADihwCkQySXPWIYNyIKzpBBAE8pZVTBhDGABgulS61QyQtkMPYy5W12rvbONdt-q01atF7k6znCScMHS9EACez-ye9d9DeB71VhfQh0-Ad3gFc0ylgYXhAeUjGjpOu8dVH_ZBKujcLVTQbg6Clej8HBzd4ofigbM38Wv4QA8jwAEIQcLTvnSQluCsQ7KXpnO_hP_AzXMjwE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2883583116</pqid></control><display><type>article</type><title>End-stage heart failure: The future of heart transplant and artificial heart</title><source>Elsevier ScienceDirect Journals</source><creator>Bounader, Karl ; Flécher, Erwan</creator><creatorcontrib>Bounader, Karl ; Flécher, Erwan</creatorcontrib><description>In the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged heart failure, as bridge to transplant or as definitive implantation in non-transplant candidates. Although clinical results do not overcome those of HTx, improvement in the new generation of devices may help to reach the equipoise between the two therapies. This review will go through the evolution, current status and perspectives of both therapeutics.</description><identifier>ISSN: 0755-4982</identifier><identifier>EISSN: 2213-0276</identifier><identifier>DOI: 10.1016/j.lpm.2023.104191</identifier><identifier>PMID: 37898310</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Cardiology and cardiovascular system ; Human health and pathology ; Life Sciences</subject><ispartof>La Presse médicale (1983), 2024-03, Vol.53 (1), p.104191-104191, Article 104191</ispartof><rights>2023 Elsevier Masson SAS</rights><rights>Copyright © 2023 Elsevier Masson SAS. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-b0b256b0fdee042e62e196968380de9b634b7e24263fb37dde07e73acaa593123</citedby><cites>FETCH-LOGICAL-c387t-b0b256b0fdee042e62e196968380de9b634b7e24263fb37dde07e73acaa593123</cites><orcidid>0000-0002-5410-7917</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0755498223000283$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37898310$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-rennes.hal.science/hal-04467355$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Bounader, Karl</creatorcontrib><creatorcontrib>Flécher, Erwan</creatorcontrib><title>End-stage heart failure: The future of heart transplant and artificial heart</title><title>La Presse médicale (1983)</title><addtitle>Presse Med</addtitle><description>In the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged heart failure, as bridge to transplant or as definitive implantation in non-transplant candidates. Although clinical results do not overcome those of HTx, improvement in the new generation of devices may help to reach the equipoise between the two therapies. This review will go through the evolution, current status and perspectives of both therapeutics.</description><subject>Cardiology and cardiovascular system</subject><subject>Human health and pathology</subject><subject>Life Sciences</subject><issn>0755-4982</issn><issn>2213-0276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAQhi0EoqXwA1hQRhhS_JHYMUxVVShSJJYyW058oa7yUeykEv8eVymMTOe7e-6V_CB0S_CcYMIfd_N638wppiz0CZHkDE0pJSzGVPBzNMUiTeNEZnSCrrzfYUxJIuQlmjCRyYwRPEX5qjWx7_UnRFvQro8qbevBwVO02UJUDX14R111WvZOt35f67aPdGuiMLKVLa2ux_01uqh07eHmVGfo42W1Wa7j_P31bbnI45Jloo8LXNCUF7gyADihwCkQySXPWIYNyIKzpBBAE8pZVTBhDGABgulS61QyQtkMPYy5W12rvbONdt-q01atF7k6znCScMHS9EACez-ye9d9DeB71VhfQh0-Ad3gFc0ylgYXhAeUjGjpOu8dVH_ZBKujcLVTQbg6Clej8HBzd4ofigbM38Wv4QA8jwAEIQcLTvnSQluCsQ7KXpnO_hP_AzXMjwE</recordid><startdate>202403</startdate><enddate>202403</enddate><creator>Bounader, Karl</creator><creator>Flécher, Erwan</creator><general>Elsevier Masson SAS</general><general>Elsevier Masson [1983-....]</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-5410-7917</orcidid></search><sort><creationdate>202403</creationdate><title>End-stage heart failure: The future of heart transplant and artificial heart</title><author>Bounader, Karl ; Flécher, Erwan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-b0b256b0fdee042e62e196968380de9b634b7e24263fb37dde07e73acaa593123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cardiology and cardiovascular system</topic><topic>Human health and pathology</topic><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bounader, Karl</creatorcontrib><creatorcontrib>Flécher, Erwan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>La Presse médicale (1983)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bounader, Karl</au><au>Flécher, Erwan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>End-stage heart failure: The future of heart transplant and artificial heart</atitle><jtitle>La Presse médicale (1983)</jtitle><addtitle>Presse Med</addtitle><date>2024-03</date><risdate>2024</risdate><volume>53</volume><issue>1</issue><spage>104191</spage><epage>104191</epage><pages>104191-104191</pages><artnum>104191</artnum><issn>0755-4982</issn><eissn>2213-0276</eissn><abstract>In the last decades, outcomes significantly improved for both heart transplantation and LVAD. Heart transplantation remains the gold standard for the treatment of end stage heart failure and will remain for many years to come. The most relevant limitations are the lack of grafts and the effects of long-term immunosuppressive therapy that involve infectious, cancerous and metabolic complications despite advances in immunosuppression management. Mechanical circulatory support has an irreplaceable role in the treatment of end-staged heart failure, as bridge to transplant or as definitive implantation in non-transplant candidates. Although clinical results do not overcome those of HTx, improvement in the new generation of devices may help to reach the equipoise between the two therapies. This review will go through the evolution, current status and perspectives of both therapeutics.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>37898310</pmid><doi>10.1016/j.lpm.2023.104191</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-5410-7917</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0755-4982
ispartof La Presse médicale (1983), 2024-03, Vol.53 (1), p.104191-104191, Article 104191
issn 0755-4982
2213-0276
language eng
recordid cdi_hal_primary_oai_HAL_hal_04467355v1
source Elsevier ScienceDirect Journals
subjects Cardiology and cardiovascular system
Human health and pathology
Life Sciences
title End-stage heart failure: The future of heart transplant and artificial heart
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T04%3A32%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=End-stage%20heart%20failure:%20The%20future%20of%20heart%20transplant%20and%20artificial%20heart&rft.jtitle=La%20Presse%20m%C3%A9dicale%20(1983)&rft.au=Bounader,%20Karl&rft.date=2024-03&rft.volume=53&rft.issue=1&rft.spage=104191&rft.epage=104191&rft.pages=104191-104191&rft.artnum=104191&rft.issn=0755-4982&rft.eissn=2213-0276&rft_id=info:doi/10.1016/j.lpm.2023.104191&rft_dat=%3Cproquest_hal_p%3E2883583116%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2883583116&rft_id=info:pmid/37898310&rft_els_id=S0755498223000283&rfr_iscdi=true